Previous Article | Next Article ![]()
Infection and Immunity, December 2000, p. 6777-6784, Vol. 68, No. 12
Department of Bacteriology and Medical Mycology,
Istituto Superiore di Sanità, Rome, Italy
Received 10 July 2000/Returned for modification 3 August
2000/Accepted 31 August 2000
A 65-kDa mannoprotein (CaMp65) has long been studied as a major,
immunodominant antigen of the human opportunistic pathogen Candida albicans. An expression library of C. albicans was screened with serum from mice immunized with ScMp65
(ScW10), a Saccharomyces cerevisiae recombinant protein of
about 48 kDa. This serum recognized the CaMp65 from a cell wall extract
of C. albicans. After cloning and sequencing of the
relevant C. albicans cDNA, an open reading frame encoding a
protein of 379 amino acids was identified. Its deduced amino acid
sequence showed regions of identity with all previously characterized
tryptic fragments of CaMp65, as well as with the corresponding regions
of ScMp65. A prepeptide of 32 amino acids with signal peptidase and
Kex2 cleavage sites as well as a high number of potential
O-glycosylation sites but no N-glycosylation sites or GPI anchor were
observed in sequence studies of CaMp65. A putative adhesin RGD
sequence was also present in the C-terminal region of the molecule.
This triplet was absent in the ScMp65. The relevant gene (designated
CaMP65) was localized to chromosome R of C. albicans as determined by pulse-field gel electrophoresis. Northern blot analysis demonstrated that gene transcription was heat
inducible and associated with germ-tube formation by the fungus. A
recombinant, His6-tagged protein (rCaMp65) was expressed in
Escherichia coli under an inducible promoter. After
purification by nickel-chelate affinity chromatography, the recombinant
product was detected as a 47-kDa protein band in immunoblots with the anti-ScMp65 serum, as well as with CaMp65-specific monoclonal antibodies. Both ScMp65 and CaMp65 were assayed for antigenic stimulation in cultures of peripheral blood mononuclear cells (PBMC)
from 10 unselected human donors. While ScMp65 was substantially nonstimulatory, both rCaMp65 and the native CaMp65 were equally able to
induce lymphoproliferation of the PBMC from all the donors. In
addition, a number of CD4+ T-cell clones were generated
using a C. albicans mannoprotein fraction as an antigenic
stimulant. Several of these clones specifically responded to both the
native and the recombinant C. albicans Mp65 but not to
ScMp65. Thus, the recombinant Mp65 of C. albicans retains antigenicity and, as such, could be a valid, standardized reagent for
serodiagnostic and immunological studies.
Despite the recognized importance of
cell-mediated immunity (CMI) in the protective response against the
human opportunistic fungus Candida albicans (33,
34), few antigenic targets of this response have so far been
characterized. They include heat shock proteins, enolase, and a number
of as-yet-uncharacterized mannoproteins, some with adhesive function
(1-3, 6, 7, 9, 11, 15-18, 26, 36). The identification of
these antigens and an understanding of the mechanisms whereby they
elicit and regulate CMI is an obvious prerequisite for generation of
molecules with potential immunoprophylactic or immunotherapeutic
activity, or even for use as immunodiagnostic reagents.
We have studied a 65-kDa mannoprotein (here designated CaMp65) of
C. albicans, structural and secreted, component of the
fungus. It is particularly observed in extracellular fractions of
hyphal cells (4, 10, 20, 37-39). Our major interest in this
mannoprotein resides in its recognition by peripheral blood T cells of
practically all healthy subjects tested (9, 10, 38, 39). In
experimental models of disseminated murine candidiasis, animals
vaccinated with a low-virulence Candida strain generated a
strong and protective CMI which was promptly revealed by CaMp65
stimulation of splenocytes in vitro, as well as by a delayed-type
hypersensitivity response to this antigen in vivo (10, 27).
Moreover, a moderate yet significant level of protection was conferred
upon mice by immunization with a mannoprotein fraction containing
CaMp65 as a major antigenic, CMI-inductive component
(27-28). This protection was clearly enhanced by the
concomitant administration of interleukin-12 (IL-12) as an adjuvant
(10).
Because of these interesting and potentially useful properties, we have
recently addressed the biochemical characterization of CaMp65. A strong
homology at the protein level was found between this protein and the
glucanase or transglycosidase family of cell wall proteins of
Saccharomyces cerevisiae (8, 20, 21). Interestingly, the least similarity between CaMp65 and the yeast proteins was found in the most antigenic peptides of the N-terminus regions of CaMp65 (21). The availability of the amino acid
sequences of several tryptic and chymotryptic fragments of CaMp65
and the established sequence homology with S. cerevisiae
cell wall proteins have allowed us to clone the relevant genes of both
C. albicans and S. cerevisiae and to
express them in Escherichia coli. Here we characterize the
cloned products and show that the recombinant protein of C. albicans induces in vitro an intense CMI response by peripheral
blood mononuclear cells (PBMC) of healthy subjects and derived
CD4+ T-cell clones, with a magnitude comparable to that
previously shown by the native antigen (10, 20, 37). These
data indicate that CaMp65 provides a suitable reagent for studies of
Candida-specific CMI generation and its role in the
anti-Candida defense.
Microrganisms, growth conditions, and mannoprotein extract.
C. albicans strain BP (3, 4) was used throughout
this study. It was grown in YPD (2% glucose, 1% yeast extract, 2%
Bacto Peptone; Difco, Detroit, Mich.), Winge (0.3% yeast extract,
0.2% glucose; Difco), or modified Lee (4, 31) media, as
specified in single experiments. E. coli XL1-Blue cells
[endA1 hsdR17 supE44 thi1 recA1 gyrA96 relA1
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Generation of a Recombinant 65-Kilodalton Mannoprotein, a
Major Antigen Target of Cell-Mediated Immune Response to
Candida albicans
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
lac (F' probAB
lacIqZ
M15, Tn10) and M15
(Nals Strs Rifs
lac
ara
gal
mtl F'
recA+ uvr+)(pUHA1)] were
used as host strains for recombinant plasmids, while
E. coli HL1-Blue MRF' (
mcrA183
mcrCB-hsdSMR-mrr173 endA1 supE44 thi1 recA1 gyrA96
relA1
lac [F' proAB
lacIqZ
M15 Tn10]) and SORL
(e14
mrcA
mcrCB-hsdSMR-mrr171 sbsC
recB recJ umuC::Tn5 uvrC endA1
su thi1 gyr96 relA1
lac [F' proAB
lacIqZ
M15]) cells were the host strains
for bacteriophage
ZAPII. E. coli cells were usually grown
in L broth (1% tryptone, 0.5% yeast extract, 0.5 NaCl; pH 7.0),
Luria-Bertani (LB) plates (1% tryptone, 0.5% yeast extract, 0.5 NaCl,
1.5% agar; pH 7.0) or top agarose (1% tryptone, 0.8% NaCl, 0.6%
agarose; Boehringer, Mannheim, Germany) supplemented when necessary
with ampicillin (100 µg/ml), kanamycin (50 µg/ml), or tetracycline
(12.5 µg/ml) (Boehringer).
Oligonucleotides and PCR.
Ca33, Ca34, Ca64, and Ca65
oligonucleotides were purchased from Pharmacia. Their sequence and
specificity are shown in Table 1. PCR
reactions with S. cerevisiae or C. albicans
purified DNA were performed as previously described (26) by
using primer pairs Ca33-Ca34 and Ca64-Ca65, respectively. Briefly, the
reactions were carried out on a Gene AMP PCR System 9600 Apparatus
(Perkin-Elmer/Cetus Corp., Norwalk, Conn.) in a volume of 100 µl
containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgCl2,
200 µM concentrations of each deoxynucleotide, 50 pmol of each
primer, 1 U of Taq polymerase (Perkin-Elmer), and 100 ng of
genomic DNA template. The PCRs were done in three steps of 60 s at
94°C, 60 s at 60°C, and 120 s at 72°C (25 cycles).
|
Generation of a mouse antiserum against recombinant S. cerevisiae MP65.
PCR amplification of S. cerevisiae genomic DNA was accomplished by using the Ca33 and Ca34
primers (Table 1). The PCR product, after digestion with
BamHI and HindIII, was cloned into the
BamHI/HindIII polylinker sites of the
expression vector pDS56/RBSII6xhis/E
to give pRLV126
(26, 32), which was used to transform E. coli M15
carrying the lack repressor-producing pUHA1 plasmid (22). To
obtain a recombinant His6-ScMp65 protein, induction was
performed in LB medium containing kanamycin and ampicillin, by adding
isopropyl-
-D-thiogalactopyranoside (IPTG; Boehringer) at
a final concentration of 1 mM to a culture with an optical density at
600 nm (OD600) of 0.6, followed by an additional 5-h
incubation at 37°C. The recombinant His6-ScMp65 protein
was purified as previously described (26, 35). A hyperimmune murine serum against the purified ScMp65 was obtained by immunizing CD2F1 mice (18 to 21 g) with four intraperitoneal injections at weekly intervals of 10 µg of the recombinant product in complete (the
first two) and incomplete (the last two) Freund adjuvant. The serum
obtained had a titer of >1,280, as determined by an assay (performed
as described in reference 3) with 1 µg of the
recombinant protein used as coating antigen.
cDNA synthesis. Poly(A)+ RNA was isolated from total RNA of C. albicans (grown as hyphae for 24 h in Lee medium [4]) by an Invitrogen Micro-Fast Track mRNA Isolation Kit (Leek, The Netherlands) (26), according to the manufacturer's instructions. Reverse transcription was performed using the Stratagene ZAP-cDNA synthesis kit (La Jolla, Calif.) as described by the manufacturer.
C. albicans ZAPII cDNA library.
Purified cDNA of
C. albicans (see above) was ligated with dephosphorylated
EcoRI-XhoI
ZAPII vector arms and incubated
with in vitro packaging extracts (Stratagene), according to the
manufacturer's instructions. Recombinant phage particles were
amplified by preparing plate lysates with E. coli strain
XL1-Blue MRF', yielding 3.5 × 105 plaques. The
amplified library (initial density, 40,000 plaques/13-cm plate) was
screened with a murine antiserum generated against ScMP65 recombinant
protein (see above).
Cloning and sequencing of CaMP65 gene.
CaMP65 was subcloned from the
ZAPII recombinant phage
library into pBluescript by infecting E. coli SORL cells
(Stratagene) as described by the manufacturer. Double-stranded
dideoxy sequencing of recombinant plasmids was performed with
the Sequenase Kit (USB, Cleveland, Ohio) using primers flanking the
polylinker region of the vector and various internal CaMP65
primers. The cDNA sequence was compared to sequences in the
Saccharomyces Genome Database (Stanford University) by using
the BLAST search. The EMBL database accession no. was AJ010064.
Southern blot analysis. Genomic DNA of C. albicans was restricted and hybridized with the full-length CaMP65 probe essentially as previously described (19, 26, 32). Briefly, the DNA was digested with the restriction endonucleases EcoRI, BamHI, HindIII, BglII, and PstI (Boehringer), separated by agarose gel electrophoresis, and transferred onto nitrocellulose transblot membranes (Bio-Rad, Hercules, Calif.). The blotted material was hybridized with 32P-labeled randomly primed (Boehringer) CaMP65 full-length cDNA insert. Hybridization and initial washing steps were carried out as described previously (26). Filters were exposed on 3M (St. Paul, Minn.) XDA Plus film, with 3M Trimax screens, at 80°C.
Northern blot analysis of CaMP65 transcription. Total RNA from C. albicans cells grown under the conditions specified later in the text was isolated by the proteinase K method as previously described (26, 32). Approximately 5 µg of RNA per lane was run on denaturing 1.5% formaldehyde-agarose gel, transblotted to nitrocellulose filters, and hybridized with randomly prime labeled full-length CaMP65 or Act1 (25, 26) probes. Hybridization and washing were done as described elsewhere (26), with the final stringent washing step carried out in 0.1% SSC (1 × SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1% sodium dodecyl sulfate (SDS) at 70°C for 30 min.
Generation of a mouse antiserum against the purified recombinant
CaMP65.
CaMP65 was generated by PCR
amplification of the C. albicans genomic DNA using the Ca64
and Ca65 primers (Table 1). The PCR product, after digestion with
BamHI and PstI, was cloned into BamHI/PstI sites of the expression vector
pDS56/RBSII6xhis/E
to give pRLV130. Expression and
purification of the recombinant CaMp65 (rCaMp65), as well as generation
of a mouse antiserum against the purified C. albicans
protein, were performed as described above for rScMP65.
Chromosome separation and hybridization. The general procedure described by Vollrath and Davis (40), as summarized in previous reports (13, 26), was used to prepare DNA samples for pulsed-field electrophoresis and karyotype determination by contour-clamped homogenous electrophoresis field (CHEF) analysis. The electrophoretic analysis was performed with CHEF-DRII apparatus (Bio-Rad). Each gel (14.5 by 20.5 cm; 1-cm thick; 1% agarose) containing the agarose inserts of DNA was immersed in running buffer (50 mM Tris-HCl, 50 mM boric acid, 1.5 mM EDTA; pH 8.2) and run for 54 h at 150 V and 14°C with 90- to 325-s switches and a rotation angle of 120°. Gels were stained with ethidium bromide (0.5 mg/ml; 30 min), destained, and photographed under UV light. Hybridization was performed as described for Southern blot analysis, except that the labeled 5' CaMP65 fragment of about 700 bp obtained by digestion of the pRLV213 with BamHI and HindIII endonucleases was used as a probe.
Immunoblotting. Recombinant proteins from IPTG-induced and noninduced M15 (pUHA1 and pRLV130) or M15 (pUHA1 and pRLV126) cells, their purified counterparts, and cell wall extracts or secretory antigenic mannoprotein (SAM) from hyphal cells of C. albicans (4; see also below) were resuspended in sample buffer, at approximately 1 mg of protein/ml, boiled for 10 min, and subjected to 5 to 15% gradient-polyacrylamide gel eletrophoresis (PAGE). The electrophoresed materials were blotted onto nitrocellulose filters in a buffer containing 25 mM Tris, 192 mM glycine, 0.1% SDS, and 20% methanol. Filters were incubated with antibodies as described in specific experiments. In all cases, nonspecific binding of antibodies to nitrocellulose was prevented by blocking the filters with 1% bovine serum albumin in phosphate-buffered saline (PBS) for 2 h at room temperature (5). After an extensive washing with PBS, bound antibodies were detected by alkaline phosphatase-conjugated second antibodies, as described in specific experiments.
Whole-cell extracts of C. albicans grown at 22°C in Lee medium and after a shift to 37°C for 3 h were obtained by cell breakage with 0.1-mm glass beads and adsorption of mannan on a concanavalin A resin as described elsewhere (9, 26). A secreted mannoprotein-rich preparation of hyphal cells of C. albicans was obtained as described by Bromuro et al. (4).Lymphocyte proliferation assay. The procedure previously described by Ausiello et al. (1, 2) and by Torosantucci et al. (37-39) was used. Briefly, PBMC obtained from heparinated, venous, peripheral blood samples of healthy adult blood donors were washed twice and resuspended in RPMI medium (GIBCO) supplemented with 5% pooled AB serum and antibiotics (penicillin, 100 IU/ml; streptomycin, 0.1 mg/ml; GIBCO), hereafter referred to as complete medium. PBMC proliferation was measured by incubating 2 × 105 PBMC cells/well in 0.2 ml of complete medium in 96 flat-bottom microwell trays (3072 Falcon; Becton Dickinson) in triplicate in the presence of the relevant stimulants. The plates were incubated at 37°C in 5% CO2 and harvested after 7 days. Then, 0.5 µCi of [methyl-3H]thymidine (Amersham; specific activity, 2.5 Ci/mmol) was added to the culture 18 h before cell harvesting, and DNA synthesis was evaluated by measuring [3H]thymidine incorporation (3). The magnitude of lymphoproliferation was estimated by reference to the PBMC culture incubated in the absence of the antigen by calculation of the stimulation index (SI). Donors were arbitrarily classified as high, moderate, and low responders to the Candida antigen (MP65) if their SI, at an antigen concentration of 1 µg/ml, was >100, between 10 and 50, and <10, respectively. In addition, the high responders to the Candida recombinant mannoprotein were characterized by an appreciable lymphoproliferative response at as low a dose of antigen as 10 ng/ml. All reagents were of standard immunological laboratory grade and did not contain lipopolysaccharide, as verified by Limulus amebocyte assay. No lymphocyte culture or clone (see below) proliferated in the absence of mitogen or antigen.
Human CaMp65-reactive T-lymphocyte clones. PBMC from a Candida antigen high responder were cultured in complete medium in the presence of a previously characterized mannoprotein fraction (MPF2) (9, 10, 27). After 5 days, 10 U of rIL-2 per well was added to the cultures. After 4 additional days, cells were cloned by limiting dilution at 3, 1, and 0.3 cells per well, as previously described (30). After 10 to 15 days, growing cultures were expanded and finally tested for MPF2 specificity in a proliferation assay using irradiated autologous PBMC as antigen-presenting cells (APC) with or without antigen at 10 µg/ml. MPF2-specific clones were expanded and maintained in culture with 25- to 30-day cycles of restimulation with phytohemagglutinin (PHA) and irradiated PBMC. Their phenotype was determined by fluorescence-activated cell sorting cytometry as previously described (30).
| |
RESULTS |
|---|
|
|
|---|
Molecular cloning, karyotype assignment, and expression of C. albicans Mp65 gene.
The amino acid sequences of tryptic and
chymotryptic fragments of native CaMp65 were highly homologous to the
deduced Scw10 and Scw4 proteins encoded by the S. cerevisiae
open reading frames (ORFs), designated YMR305C and
YGR279, respectively (Saccharomyces cerevisiae
Genome Database) (8). On this basis, the YMR305C ORF was cloned by PCR using the Ca33 and Ca34 oligonucleotide primers
containing the initiation and stop codons of the gene (Table 1).
Molecular analysis of the amplified product (1,168 bp) confirmed the
sequence of YMR305C DNA of S. cerevisiae. This fragment was cloned into an inducible E. coli expression
vector to produce a recombinant His6-tagged protein
(designated rScMp65). A mouse serum raised against this recombinant
product was able to recognize, besides the immunogen itself, the native
MP65 of C. albicans in a cell wall extract of the fungus
(Fig. 1). The antiserum against rScMp65
was therefore used to screen a
ZAPII expression library of C. albicans, as described in Materials and Methods. Six independent
clones were isolated and purified. Molecular analysis of these clones
displayed sequence identity. The clone (clone CaRLV213, 1,415 bp)
containing both start and top codons of an ORF of 1,140 bp (designated
CaMP65) was selected for further studies. By using the BLAST
search, the nucleotide sequence of this clone was found to be 98 and
96% identical to contigs 5-2183 and 5-2970, respectively, of the
Stanford Candida Genome Database.
|
|
|
|
|
Generation of recombinant CaMp65 protein.
pRLV130-transformed
E. coli cells were cultured in antibiotic LB broth, and
total cell protein extracts, under induced or uninduced
conditions, were subjected to SDS-PAGE, Coomassie blue staining, and Western blotting with various antibodies. As
shown in Fig. 6a, a novel, prominent
protein was detected in the extract of induced E. coli, as
revealed by Coomassie blue staining. Figure 6b shows the positive
reaction of this recombinant protein (with an apparent molecular mass
of ca. 47 kDa) and of the MP65-rich secretion from the hyphal cells,
but not of the ScMP65, with the anti-MP65 monoclonal antibody 4C8. As
expected from previous data (20), most of the reactivity of
the monoclonal antibody 4C8 with the mycelial secretion was detected in
a molecular mass region roughly corresponding to 65 kDa, i.e., the
native glycosylated Mp65 of C. albicans (Fig. 6b). The
recombinant product was also reactive with another
monoclonal antibody (7H8) raised against the native CaMp65
and was also recognized by the antiserum raised against the purified
recombinant ScMp65 (data not shown).
|
Antigenicity of the recombinant CaMp65.
The recombinant CaMp65
and ScMp65, together with the native Mp65 of C. albicans and
control antigen, were tested for reactivity with PBMC from healthy
human subjects. Table 2 shows the
lymphoproliferation data from three blood donors with different degrees
of responsiveness to the antigenic stimulation out of the 10 examined
with similar results. The recombinant protein of C. albicans
was roughly as effective, at equal doses, as the native protein of the
fungus. In particular, no subject tested was unresponsive to the
recombinant, as well as to the native candidal protein, and the two
antigens induced comparable responses in high (donor 1)-, intermediate (donor 2)-, and low (donor 3)-responder subjects (Table 2). Remarkably, in the high-responder donors, low doses of rCaMp65 (10 ng/ml) were
still effective at inducing lymphoproliferation. The recombinant protein of S. cerevisiae was minimally effective in
stimulating cell proliferation even in the high-grade responder shown
in Table 2 (see also below).
|
Generation of CaMP65-specific human T-cell clones.
Forty-five T-cell clones were generated from a high-responder subject
to a mannoprotein fraction (MPF2) of C. albicans. All of
them were of the CD4+ T-cell phenotype. Several of these
clones were specific for CaMp65. Figure 7
shows the proliferation of four representative clones following
activation with different stimuli in the presence of irradiated
autologous PBMC. All of the clones proliferated when stimulated with
MPF2 and showed a remarkable increase in the
[3H]thymidine incorporation following stimulation with
CaMp65. The proliferation in the presence of rCaMp65 was of the same
order of magnitude as that obtained with the native mannoprotein. With both the native and the recombinant Candida antigens, the
values of [3H]thymidine incorporation were similar to
those of PHA-stimulated clones. Importantly, none of the
CaMp65-reactive clones responded to the recombinant ScMp65.
|
| |
DISCUSSION |
|---|
|
|
|---|
In this study, data on molecular cloning, expression, and characterization of recombinant Mp65, a protein which has long been identified as a major target of CMI response against the human opportunistic fungus C. albicans (10, 20, 21, 37-39), have been presented. Instrumental to this (and as an immunogenicity control), a recombinant protein of S. cerevisiae (rScmp65), corresponding to the Scw10 protein previously characterized by Cappellaro et al. (8), was also generated. A serum against this protein was raised in mice and used to screen a C. albicans library for homologous genes.
Besides sequence homology with previously characterized proteolytic fragments of natural Mp65 (21), the recombinant product of C. albicans (but not that of S. cerevisiae) reacted in Western blots with two monoclonal antibodies raised against the purified natural product, demonstrating that, as previously suggested (21), these antibodies recognize a peptide rather than a saccharide epitope of C. albicans protein. Moreover, a mouse serum from animals immunized with the S. cerevisiae recombinant product specifically reacted in immunoblots with the natural C. albicans Mp65. Altogether, these data leave little doubt that the recombinant product fully corresponds to a nonglycosylated antigenically functional form of C. albicans mannoprotein (see also below).
Previous biochemical characterization of the native CaMp65 indicated a substantial glycosylation of this protein, occurring as acid-labile O side chains with numerous serine and threonine residues, which together accounted for about 20% of the whole amino acid composition (20, 21). The deduced amino acid sequence of CaMP65 cDNA, as well as the determination of the molecular mass of the recombinant product, indicates a molecular mass of about 45 kDa; thus, glycosylation of the natural product would account for about one-third of its mass. Previous findings indirectly suggested that most of the glycosylation occurs at a long protein stretch where repeated serine-threonine sequence blocks were present (21). This was confirmed here by deducing the amino acid sequence of the cloned gene, a sequence which also confirmed the lowest homology between the two proteins in the immunodominant N-terminal region of CaMp65 (see also below). In contrast to the homologous protein of S. cerevisiae (8), no potential N-glycosylation site was present in the Mp65 deduced amino acid sequence. This confirms the previous determination (21) of the amino acid sequence of tryptic and chymotryptic fragments of the natural Mp65, inclusive of the region containing the potential N-glycosylation triplet of S. cerevisiae (NYS; aa 279). It is also in keeping with the resistance of natural Mp65 to digestion with endo-N and -F glycosidases (20, 38). Overall, the natural C. albicans Mp65 appear to be only O glycosylated, as in some other fungal mannoproteins (23). The presence of a prepeptide with a signal sequence for processing in the endoplasmic reticulum, as well as with the KR doublet of a Kex-like peptidase before the amino terminus start, clearly confirms the nature of a secretory mannoprotein which was already inferred from functional studies (3, 4).
Another interesting and perhaps functionally relevant difference between CaMp65 and Scw10-Scw4 proteins (8) is the presence of a RGD site in the C. albicans mannoprotein. This site has repeatedly been shown to characterize some integrin-like proteins of C. albicans, including a complement-like receptor of the fungus. In this context, RGD-containing molecules have been implicated in the increased adherence of hyphal cells of C. albicans to plastic and animal cells (6). One of these adhesins was previously characterized as a 60- to 65-kDa protein but its sequence was not determined (7). The data would suggest a role of "secretory adhesin" for CaMp65, and we are currently working on determining the functional features of this mannoprotein.
CaMp65 and the closest homologous Scw10 probably belong to a family of enzymes of glucan metabolism (glucanases or transglycosidases) (8). Since both rCaMp65 and rScMp65 have been here expressed under denaturing conditions, they could not be tested for their possible enzymatic activity. However, a number of observations suggest that these kinds of proteins are indeed involved in cell wall metabolism. The natural Mp65 could be preferentially purified from the hyphal secretory materials under tunicamycin inhibition of glycosylation (21), and much more immunogenic Mp65-containing, secretory mannoprotein material was obtained from hypha- than from yeast-growing cells (4, 37). The higher CaMP65 gene transcription at 37 to 42°C than at 22 to 28°C is more in keeping with the conditions favoring mycelial rather than yeast cell growth of C. albicans (31). However, more specific and quantitative expression studies are required before drawing a definitive conclusion regarding this.
rCaMp65 has been shown here to be highly antigenic and immunogenic. As with the natural mannoprotein, it was able to stimulate in vitro proliferation of lymphocytes from all of the normal subjects tested so far. Also, the magnitude of the proliferative response was comparable to that recorded in the same subjects under stimulation with the natural product. Moreover, the recombinant product was as efficient as the native mannoprotein in stimulating specific T-cell clones, indicating that the recombinant protein gains access to the endocytic compartment of the APC and that it is processed to generate the same peptides generated by the processing of the natural protein. Interestingly, the recombinant product of S. cerevisiae was much less effective at inducing, if not totally unable to induce, PBMC lymphoproliferation. Despite an overall rather large homology between the two proteins, there are several peptide regions of CaMp65 where this homology is rather low. Strong proliferation-inducing peptide fragments of the native CaMp65 were among those showing the least similarity with the corresponding peptide sequences of S. cerevisiae homologs Scw10 and Scw4 (21). These highly antigenic MP65 epitopes were found in the N-terminus region of CaMp65, suggesting that, as happens for other O-linked, saccharide-rich cell wall proteins of C. albicans (11), the N-terminal region of the mannoprotein is the one more likely to be exposed on the cell surface or accessible to immunocompetent cells. This idea is clearly in line both with the immunodominance of the molecule and with its potential adhesive role. In agreement with the data obtained with PBMC proliferation, none of the CaMp65-specific clones was stimulated by ScMp65. These data confirm that the immunogenic epitopes of CaMp65 are enriched with those regions of the protein sharing the least homology with the S. cerevisiae mannoprotein.
Thus, this C. albicans putative glucanase protein seems to have acquired rather unique antigenic properties among members of this family of cell wall proteins, in keeping with its cell wall expression, and human commensalism of the fungus. Interestingly, this marked immunogenicity seems to be preferentially addressed to the cell-mediated arm of host immune response, since normal human sera, which are usually rich in anti-Candida antibodies (31), show rather low reactivity with the natural or the recombinant Mp65 protein (unpublished data).
Several data have long suggested that peptide epitopes of the highly immunogenic mannoproteins of C. albicans were those inducing and revealing CMI (9, 10, 16, 17, 29, 38). The high frequency of responses by PBMC and T-cell clones to the whole recombinant protein detected in normal, healthy subjects further supports the above assumption. This is not to say, however, that the presumably numerous O-saccharide chains present on the natural Mp65 of C. albicans do not participate in CMI recognition, either enhancing or downmodulating the response. Recent evidence points to this possibility (14), as well as to the capacity of selected lymphocyte populations with gamma or delta T-cell receptors to start an adaptive cellular response against lipidated or nonlipidated polysaccharides. A comparison of the stimulating capacity of suitably designed synthetic peptides with the corresponding natural ones may help to distinguish between the two events. The generation of human T-cell clones against the recombinant protein will help to obtain further insight into the mechanisms of CaMp65 recognition and processing. The provision of a highly immunogenic, recombinant product of a common recall antigen may prove useful for all studies addressing the state of immune response to Candida and its modulation during disease (e.g., in AIDS or other immunodeficiencies), which greatly predispose to infection by this fungus (24, 34). In contrast to the natural Mp65, the recombinant product can be obtained in large quantities and can be standardized for purity, potency, and overall quality.
| |
ACKNOWLEDGMENTS |
|---|
We thank A. Botzios, C. Belotti, and F. Girolamo for help in manuscript preparation.
This work was in part supported by a grant from the National AIDS Program (contract 50 C/B).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Bacteriology and Medical Mycology, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy. Phone: 39-06-49387113. Fax: 39-06-49387112. E-mail: cassone{at}iss.it.
Editor: T. R. Kozel
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Ausiello, C. M.,
G. C. Spagnoli,
M. Boccanera,
I. Casalinuovo,
F. Malavasi,
C. U. Casciani, and A. Cassone.
1986.
Proliferation of human peripheral blood mononuclear cells induced by Candida albicans and its cell wall fractions.
J. Med. Microbiol.
22:195-202 |
| 2. |
Ausiello, M. C.,
F. Urbani,
S. Gessani,
G. C. Spagnoli,
M. J. Gomez, and A. Cassone.
1993.
Cytokine gene expression in human peripheral blood mononuclear cells stimulated by mannoprotein constituents from Candida albicans.
Infect. Immun.
61:4105-4111 |
| 3. |
Bromuro, C.,
R. La Valle,
S. Sandini,
F. Urbani,
C. M. Ausiello,
L. Morelli,
C. Fè d'Ostiani,
L. Romani, and A. Cassone.
1998.
A 70-kDa recombinant heat shock protein of C. albicans is highly immunogenic and enhances systemic murine candidiasis.
Infect. Immun.
66:2154-2162 |
| 4. | Bromuro, C., A. Torosantucci, M. J. Gomez, F. Urbani, and A. Cassone. 1994. Differential release of an immunodominant 65-kDa mannoprotein antigen from yeast and mycelial forms of Candida albicans. J. Med. Vet. Mycol. 32:447-459[Medline]. |
| 5. | Burnette, N. 1981. "Western blotting": electrophoretic transfer of protein from dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal. Biochem. 112:195-203[CrossRef][Medline]. |
| 6. | Calderone, R., E. Enache, T. Eskandri, E. Wadsworth, and J. Sturtevant. 1997. Adherence of Candida albicans to mammalian cells in vitro: nutritional influences, p. 73-83. In S. Suzuki, and M. Suzuki (ed.), Fungal cells in biodefense mechanism. Saikon Publishing Co., Ltd., Tokyo, Japan. |
| 7. |
Calderone, R. A.,
L. Linehan,
E. Wadsworth, and L. Sandberg.
1988.
Identification of C3d receptors on Candida albicans.
Infect. Immun.
56:252-258 |
| 8. | Cappellaro, C., V. Marsa, and W. Tanner. 1998. New potential cell wall glucanases of Saccharomyces cerevisiae and their involvement in mating. J. Bacteriol. 18:5030-5037. |
| 9. | Cassone, A., and A. Torosantucci. 1991. Immunological moieties of the cell wall, p. 89-107. In R. Prasad (ed.), Candida albicans. Springer-Verlag, Berlin, Germany. |
| 10. | Cassone, A., F. De Bernardis, C. M. Ausiello, M. J. Gomez, M. Boccanera, R. La Valle, and A. Torosantucci. 1998. Immunogenic and protective Candida albicans constituents. Res. Immunol. 149:289-298[CrossRef][Medline]. |
| 11. |
Chaffin, W. L.,
J. L. Lopez-Ribot,
M. Casanova,
D. Gozalbo, and J. M. Martinez.
1988.
Cell wall secreted proteins of Candida albicans: identification, function and expression.
Microbiol. Mol. Biol. Rev.
62:130-180 |
| 12. |
De Bernardis, F.,
A. Molinari,
M. Boccanera,
A. Stringaro,
R. Robert,
J. M. Senet,
G. Arancia, and A. Cassone.
1994.
Modulation of cell surface-associated mannoprotein antigen expression in experimental candidal vaginitis.
Infect. Immun.
62:509-519 |
| 13. |
De Bernardis, F.,
F. Mondello,
R. San Millan,
J. Ponton, and A. Cassone.
1999.
Biotyping and virulence properties of skin isolates of Candida parapsilosis.
J. Clin. Microbiol.
37:3481-3486 |
| 14. |
Deck, M. B.,
P. Sjölin,
E. R. Unanue, and J. Kihlber.
1999.
MHC-restricted, glycopeptide-specific T cells shows specificity for both carbohydrate and peptide residues.
J. Immunol.
162:4740-4744 |
| 15. | Deepe, G. S., Jr. 1997. Prospects for the development of fungal vaccines. Clin. Microbiol. Rev. 10:585-596[Abstract]. |
| 16. | Domer, J. E. 1989. Candida cell wall mannan: a polysaccharide with diverse immunologic properties. Crit. Rev. Immunol. 17:33-51. |
| 17. | Domer, J. E., S. Li, Y. Wang, and S. Lee. 1997. Immunoregolatory studies with Candida albicans mannan. In S. Suzuki, and M. Suzuki (ed.), Fungal cells in biodefense mechanism. Saikon Publishing Co., Ltd., Tokyo, Japan. |
| 18. | Gilmore, B. J., E. M. Retsinas, J. S. Lorenz, and M. K. Hostetter. 1988. An iC3b receptor on Candida albicans: structure, function and correlates for pathogenicity. J. Infect. Dis. 157:38-41[Medline]. |
| 19. | Glover, D. M. 1985. DNA cloning: a practical approach. IRL Press, Oxford, England. |
| 20. | Gomez, M. J., A. Torosantucci, S. Arancia, B. Maras, L. Parisi, and A. Cassone. 1996. Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of anti-Candida cell-mediated immune responses in humans. Infect. Immun. 64:2577-2584[Abstract]. |
| 21. |
Gomez, M. J.,
B. Maras,
A. Barca,
R. La Valle,
D. Barra, and A. Cassone.
2000.
Biochemical and immunological characterization of MP65, a major mannoprotein antigen of the opportunistic human pathogen Candida albicans.
Infect. Immun.
68:694-701 |
| 22. | Hochuli, E., W. Bannwarth, H. Dobli, R. Gentz, and D. Stuber. 1988. Genetic approach to facilitate purification of recombinant proteins with a novel metal-chelate absorbant. Bio/Technology 6:1321-1325[CrossRef]. |
| 23. | Kapteyn, J. C., H. Van Den Ende, and F. M. Klis. 1999. The contribution of cell wall proteins to the organization of the yeast cell wall. Biochim. Biophys. Acta 1426:373-383[Medline]. |
| 24. | Klein, R. S., C. A. Harris, C. B. Small, B. Moll, M. Lesser, and G. H. Friedland. 1984. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311:354-358[Abstract]. |
| 25. | Lasker, A. A., and W. S. Riggsby. 1992. Transcription of the single actin gene of Candida albicans during the yeast-to-mycelium conversion. Exp. Mycol. 161:155-162[CrossRef]. |
| 26. | La Valle, R., C. Bromuro, L. Ranucci, H. M. Muller, A. Crisanti, and A. Cassone. 1995. Molecular cloning and expression of 70-kilodalton heat shock protein of Candida albicans. Infect. Immun. 63:4039-4045[Abstract]. |
| 27. |
Mencacci, A.,
A. Torosantucci,
R. Spaccapelo,
L. Romani,
F. Bistoni, and A. Cassone.
1994.
A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice.
Infect. Immun.
62:5353-5360 |
| 28. | Mencacci, A., R. Spaccapelo, G. Del Sero, K. H. Essle, A. Cassone, F. Bistoni, and L. Romani. 1996. CD4+ T-helper cell responses in mice with low-level Candida albicans infection. Infect. Immun. 64:4907-4914[Abstract]. |
| 29. |
Nelson, R. D.,
N. Shibata,
P. R. Podzorski, and M. J. Herror.
1991.
Candida mannan: chemistry, suppression of cell-mediated immunity, and possible mechanisms of action.
Clin. Microbiol. Rev.
4:1-19 |
| 30. | Nisini, R., M. Paroli, D. Accapezzato, F. Bonino, F. Rosina, T. Santantonio, F. Sallusto, A. Amoroso, M. Houghton, and V. Barnaba. 1997. Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J. Virol. 71:2241-2251[Abstract]. |
| 31. | Odds, F. C. 1988. Candida and candidosis, 2nd ed. Baillière Tindall, London, England. |
| 32. | Perbal, B. 1988. A practical guide to molecular cloning. Wiley-Interscience Publications, New York, N.Y. |
| 33. | Puccetti, P., L. Romani, and F. Bistoni. 1995. A TH-1-TH-2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol. 3:237-240[CrossRef][Medline]. |
| 34. | Romani, L., and D. H. Howard. 1995. Mechanisms of resistance to fungal infection. Curr. Opin. Immunol. 7:517-523[CrossRef][Medline]. |
| 35. | Stuber, D., H. Matile, and G. Garotta. 1990. System for high-level production in E. coli and rapid purification of recombinant proteins: application to epitope mapping preparation of antibodies and structure/function analysis, p. 121-152. In I. Lefkovitz, and B. Pernis (ed.), Immunological methods, vol. 4. Academic Press, Inc., Orlando, Fla. |
| 36. | Sundstrom, P., J. Jensen, and E. Balish. 1994. Humoral and cellular immune response to enolase after alimentary tract colonization or intravenous immunization with Candida albicans. J. Infect. Dis. 170:390-395[Medline]. |
| 37. | Torosantucci, A., C. Palma, M. Boccanera, C. M. Ausiello, G. C. Spagnoli, and A. Cassone. 1990. Lymphoproliferation and cytotoxic responses of human peripheral blood mononuclear cells to mannoprotein constituents of Candida albicans. J. Gen. Microbiol. 136:664-672. |
| 38. | Torosantucci, A., M. J. Gomez, C. Bromuro, J. Casalinuovo, and A. Cassone. 1991. Biochemical and antigenic characterization of mannoprotein constituents released from yeast and mycelial form of Candida albicans. J. Med. Vet. Mycol. 29:361-372[Medline]. |
| 39. | Torosantucci, A., C. Bromuro, M. J. Gomez, C. M. Ausiello, F. Urbani, and A. Cassone. 1993. Identification of a 65-kDa mannoprotein as a main target of human cell-mediated immune response to Candida albicans. J. Infect. Dis. 168:427-435[Medline]. |
| 40. |
Vollrath, D., and R. W. Davis.
1987.
Resolution of greater than megabasepair DNA molecules by contour clamped homogeneous electric fields.
Nucleic Acids Res.
15:7865-7866 |
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»